Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified

Patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have diffuse large cell or diffuse mixed lymphoma that expresses a cell surface phenotype of a postthymic (or peripheral) T-cell expressing either CD4 or, less often, CD8.[1] PTCL-NOS encompasses a group of heterogeneous nodal T-cell lymphomas that will require future delineation.[2,3] Gene expression profiling studies have identified two distinct subtypes of PTCL-NOS based on the transcription factors GATA3 and TBX21. Early investigation and anecdotal reports suggest these subtypes may carry important prognostic implications and could predict response to certain therapies.[4] Additional studies are needed for further characterization of their clinical relevance.